Next generation human microbiome therapeutics.



The human microbiome has emerged as a key driver of immune dysfunction. At Siolta Therapeutics, we leverage multi-scale next-generation microbiome analyses to develop and test microbial-based therapeutics for induction and maintenance of immune tolerance.


Shiel | ta

Gaelic: seeds

Microbial seeds for human microbiome management.


At Siolta Therapeutics, we harness information from human microbiome studies to design next-generation microbial therapeutics that re-engineer the human microbiome to prevent or reduce inflammatory processes.


Founders / Team


Khosla Ventures

Marc Benioff


Join Our Team

Our research focuses on microbial communities associated with chronic inflammatory diseases of the gastrointestinal and respiratory tracts. Using clinical samples to inform studies using murine models, we examine relationships between microbial community composition and function in an effort to better understand microbial-host interplay in the context of chronic inflammatory disease.

Current Openings


Bioinformatics / Microbiome Sciences

Siolta Therapeutics is seeking highly motivated and talented technical staff scientists to provide support for the company’s therapeutic development program focused on prevention/treatment of airway inflammation through manipulation of the gut microbiome. The successful candidate will work closely with other team members on preclinical studies of a rationally designed mixedspecies therapeutic microbial consortium. The successful candidate will be technically proficient in microbial culture, molecular techniques and experienced in animal handling.

To Apply:

Please provide a cover letter, CV, and three references. Salary will be dependent on the experience of individual applicants and will include full benefits.


November 2017

5th Microbiome R&D and Business Collaboration Forum

Join Siolta on November 3rd at the 5th Microbiome R&D and Business Collaboration Forum: USA (2:20pm Dockside)

Read More

August 2017

California Life Sciences Institute (CLSI) Fellows All-Star Team

Thanks to California Life Science Institute (CLSI) for choosing Siolta Therapeutics to participate in the Fall 2017 Fellows All-Star Team (FAST) Advisory Program. California Life Sciences Institute (CLSI) maintains California’s leadership in life sciences innovation through support of entrepreneurship, education and career development.

Read More

April 2017

3rd Annual Translational Microbiome Conference

Translating the Microbiome From the Bench to Bedside: Challenges and Opportunities in Developing bioTherapeutics and Diagnostics - April 12-13th, Boston, MA The Colonnade Hotel

Founder and Vice President, Dr. Nikole Kimes, will be presenting Next Generation Microbial Therapeutics: Challenges in Transforming the Therapeutic Landscape for Atopy and Asthma

Read More

January 2017

Precision Medicine World Conference 2017

Come hear more about Siolta Therapeutics at the Precision Medicine World Conference 2017 in Palo Alto Jauary 24th

Read More

December 2016

The Human Intestinal Microbiome in Health and Disease

Check out this great microbiome review by Founder, Dr. Susan Lynch, and her colleague, Dr. Oluf Pedersen, in the New England Journal of Medicine

Read More